# Fluticasone-Vilanterol

## Relvar Ellipta 92/22mcg inhalation powder

| 藥物代碼 | ERELV |
| :--- | :--- |
| 適應症 | Asthma: Treatment of asthma in patients &gt;=18 years.Chronic obstructive pulmonary disease: Maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease \(COPD\), including chronic bronchitis and/or emphysema; to reduce exacerbations of COPD in patients with a history of exacerbationsFluticasone 100 mcg/vilanterol 25 mcg is the only strength indicated for the treatment of COPD. |
| 副作用 | 1% to 10%:Cardiovascular: Hypertension \(&gt;3%\), peripheral edema \(&gt;3%\), extrasystoles \(&gt;2%\), supraventricular extrasystole \(&gt;2%\), ventricular premature contractions \(&gt;2%\)Central nervous system: Headache \(5% to 8%\)Gastrointestinal: Oropharyngeal candidiasis \(2% to 5%\), diarrhea \(&gt;3%\), upper abdominal pain \(&gt;2%\)Infection: Influenza \(&gt;3%\)Neuromuscular & skeletal: Arthralgia \(2% to &gt;3%\), back pain \(2% to &gt;3%\), bone fracture \(2%\)Respiratory: Nasopharyngitis \(6% to 10%\), upper respiratory tract infection \(&gt;2% to 7%\), pneumonia \(2% to 7%\), oropharyngeal pain \(2% to ?3%\), pharyngitis \(2% to ?3%\), chronic obstructive pulmonary disease \(?3%\), cough \(1% to 3%\), sinusitis \(1% to 3%\), bronchitis \(3%\), acute sinusitis \(2%\), allergic rhinitis \(2%\), rhinitis \(2%\), viral respiratory tract infection \(2%\), voice disorder \(2%\)Miscellaneous: Fever \(2% to 3%\)&lt;1%, postmarketing, and/or case reports: Anaphylaxis, angioedema, cataract, glaucoma, hypersensitivity reaction, muscle spasm, nervousness, palpitations, paradoxical bronchospasm, skin rash, tachycardia, tremor, urticaria |
| 禁忌 | Hypersensitivity to fluticasone, vilanterol or any component of the formulation; severe hypersensitivity to milk proteins; primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required |
| 藥物保存方式 | 室溫 |
| 用法用量 | One inhalation of Relvar Ellipta 92/22 micrograms once daily. |
| 肝功能異常 | 無需調整劑量 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | N/A |
| 附帶說明 | FLUTICASONE PREGNANCY RECOMMENDATION: Compatible |
| 哺乳期用藥建議 | Unknown 尚未建立 |
| 附帶說明 | FLUTICASONE BREASTFEEDING RECOMMENDATION: No Human Data—Probably Compatible |
| 注射劑給藥建議途徑 | IH |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

